Stock Analysis
- Hong Kong
- /
- Healthcare Services
- /
- SEHK:1345
Shanghai Pioneer Holding Full Year 2023 Earnings: EPS: CN¥0.12 (vs CN¥0.20 in FY 2022)
Shanghai Pioneer Holding (HKG:1345) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥1.57b (flat on FY 2022).
- Net income: CN¥145.7m (down 38% from FY 2022).
- Profit margin: 9.3% (down from 15% in FY 2022).
- EPS: CN¥0.12 (down from CN¥0.20 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Pioneer Holding shares are down 2.1% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Shanghai Pioneer Holding (including 1 which is a bit concerning).
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:1345
Shanghai Pioneer Holding
An investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People’s Republic of China.